Afatinib based drugs

Afatinib is not just another inhibitor; it acts as an irreversible "master lock" on cancer growth. Unlike older drugs that can detach over time, Afatinib binds permanently to cancer cell receptors. It shuts down the entire ErbB signaling family network, leaving the tumor with no escape routes to grow. It is a powerful first-line defense for patients with EGFR-mutated non-small cell lung cancer (NSCLC), offering a deeper and more durable response than standard therapies.